Echinomycin (NSC 526417) in advanced ovarian cancer. A phase II trial of the Gynecologic Oncology Group.
Twenty-two patients with recurrent carcinoma of the ovary progressive after initial chemotherapy (21 with cisplatin-based treatment) were entered on a phase II trial utilizing Echinomycin at a dosage of 1,500 micrograms/m2 every 4 weeks. There were two complete responders and no partial responders (9% response, 95% confidence intervals for complete and partial responses of 1-29%). Major toxicity was modest and consisted mainly of nausea and vomiting. Echinomycin displays minimal activity as salvage therapy in women with advanced ovarian cancer at this dose and schedule.
Bowman Gray School of Medicine, Wake Forest University, Winston-Salem, North Carolina.
H B
HB
Muss
J A
JA
Blessing
V V
VV
Baker
D R
DR
Barnhill
M D
MD
Adelson
D000328:Adult; D000368:Aged; D002277:Carcinoma / Q000188:drug therapy*; D004341:Drug Evaluation; D004448:Echinomycin / Q000008:administration & dosage / Q000627:therapeutic use* / Q000633:toxicity; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D009364:Neoplasm Recurrence, Local; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D011810:Quinoxalines / Q000627:therapeutic use*; D012074:Remission Induction
D011810:Quinoxalines; D004448:Echinomycin